Frontiers in cellular and infection microbiology · 2026
Bacteriophage FNU1 negates Fusobacterium nucleatum induced cell growth, migration and chemotherapy resistance in gastrointestinal cancer cells.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kabwe Mwila, Ayelign Birhanu, Afshar-Sterle Shoukat, Buchert Michael, Tucci Joseph
Аннотация
BACKGROUND: Fusobacterium nucleatum is an oncobacterium capable of promoting the growth and chemotherapy resistance of colonised tumours. Although F. nucleatum is usually susceptible to a range of antibiotics in vitro, these have been associated with worse outcomes when administered with anti-neoplastic chemotherapy. Bacteriophages are viewed as natural alternatives to antibiotics that provide bacterial-specific targeting.
METHODS: In this study, we have employed an F. nucleatum specific bacteriophage, FNU1, to limit the effects of this oncobacteria in colon cancer and gastric cancer cell models.
RESULTS: We demonstrated that FNU1 was able to negate the F. nucleatum induced growth stimulatory effects, migratory ability, autophagy, anti-apoptotic effects and chemotherapy resistance in these cell models.
CONCLUSION: Treatments with bacteriophage FNU1, therefore, have the potential to augment existing cancer therapy, and further testing in animal models is warranted.
METHODS: In this study, we have employed an F. nucleatum specific bacteriophage, FNU1, to limit the effects of this oncobacteria in colon cancer and gastric cancer cell models.
RESULTS: We demonstrated that FNU1 was able to negate the F. nucleatum induced growth stimulatory effects, migratory ability, autophagy, anti-apoptotic effects and chemotherapy resistance in these cell models.
CONCLUSION: Treatments with bacteriophage FNU1, therefore, have the potential to augment existing cancer therapy, and further testing in animal models is warranted.